Mirae Asset Global Investments Co. Ltd. Purchases 145 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Mirae Asset Global Investments Co. Ltd. increased its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 0.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 37,414 shares of the biotechnology company’s stock after acquiring an additional 145 shares during the period. Mirae Asset Global Investments Co. Ltd. owned about 0.06% of Blueprint Medicines worth $3,451,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. PNC Financial Services Group Inc. grew its holdings in shares of Blueprint Medicines by 63.4% in the third quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 329 shares during the period. Cutler Group LLC CA grew its holdings in shares of Blueprint Medicines by 1,685.7% in the third quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 944 shares during the period. Lazard Asset Management LLC bought a new stake in shares of Blueprint Medicines in the fourth quarter worth $57,000. Dark Forest Capital Management LP bought a new stake in shares of Blueprint Medicines in the first quarter worth $63,000. Finally, Compass Wealth Management LLC purchased a new position in Blueprint Medicines during the fourth quarter valued at $69,000.

Insider Activity at Blueprint Medicines

In related news, Director Jeffrey W. Albers sold 25,000 shares of the stock in a transaction that occurred on Thursday, January 25th. The stock was sold at an average price of $81.91, for a total transaction of $2,047,750.00. Following the completion of the transaction, the director now directly owns 176,050 shares of the company’s stock, valued at $14,420,255.50. The sale was disclosed in a filing with the SEC, which is available through this link. In other Blueprint Medicines news, insider Christopher K. Murray sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $100.00, for a total transaction of $500,000.00. Following the sale, the insider now directly owns 24,495 shares in the company, valued at $2,449,500. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jeffrey W. Albers sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $81.91, for a total value of $2,047,750.00. Following the sale, the director now owns 176,050 shares in the company, valued at $14,420,255.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 117,289 shares of company stock valued at $10,361,913. Insiders own 3.88% of the company’s stock.

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock opened at $86.09 on Wednesday. The stock has a 50 day moving average of $88.93 and a 200 day moving average of $76.88. Blueprint Medicines Co. has a 12 month low of $43.89 and a 12 month high of $101.00. The firm has a market cap of $5.27 billion, a PE ratio of -10.30 and a beta of 0.63. The company has a current ratio of 3.76, a quick ratio of 3.66 and a debt-to-equity ratio of 1.60.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating analysts’ consensus estimates of ($2.04) by $0.22. Blueprint Medicines had a negative return on equity of 191.56% and a negative net margin of 203.30%. The company had revenue of $71.96 million during the quarter, compared to analyst estimates of $67.34 million. During the same period in the prior year, the company earned ($2.65) earnings per share. The firm’s revenue was up 85.5% on a year-over-year basis. On average, research analysts expect that Blueprint Medicines Co. will post -5.42 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on BPMC shares. Raymond James lifted their target price on Blueprint Medicines from $85.00 to $100.00 and gave the company a “strong-buy” rating in a research report on Friday, December 22nd. Wells Fargo & Company lifted their target price on Blueprint Medicines from $86.00 to $115.00 and gave the company an “overweight” rating in a research report on Tuesday, December 19th. Needham & Company LLC reiterated a “buy” rating and set a $97.00 target price on shares of Blueprint Medicines in a research report on Monday, February 26th. Wedbush reiterated an “outperform” rating and set a $97.00 target price on shares of Blueprint Medicines in a research report on Monday, February 5th. Finally, JMP Securities reiterated a “market outperform” rating and set a $114.00 target price on shares of Blueprint Medicines in a research report on Wednesday, April 10th. Four equities research analysts have rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $85.43.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.